Scott Koenig discusses the Phase 3 SOPHIA study. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering…
Browsing: Breast
Breast Cancer
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Intravenous NEPA Study: Combination Therapy To Prevent CINV In Patients Receiving…
Hannah Linden MD Of The University of Washington School of Medicine Discusses What We Specialize In: Multidisciplinary Approach, One Stop…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Palbociclib & Alpelisib: Improved Survival Benefit In Younger…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Hired Expert In Molecular Imaging: Huge Opportunity To…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Estrogen Receptor Imaging: Specialty Diagnostic Test That Can…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-01 With a focus on integrating recent advances into improved care pathways, this on-demand…
Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, Sensoring Process, QOL. At ESMO Oncology Conference – Munich,…
Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, FDA Approval Of Talazoparib. At ESMO Oncology Conference -…
Hope Rugo, M.D., University Of California San Francisco discusses Data On Neoadjuvant Talazoparib. At ESMO Oncology Conference – Munich, Germany…
Managing side effects can be an overwhelming experience for oncology patients, they may be unsure of the severity of their…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Improving Survival in Stage 4 Breast Cancer | S0226 Showed That…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Fasching, MD, from University…
In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Avoiding Chemotherapy in Subset of Patients | TAILORx Uses Scoring Method…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Cyclin-Dependent Kinases to Endocrine Therapy | Adding CDK-46 inhibitors to Frontline…
Rita Sanghvi Mehta, MD, UC Irvine Health, explains High-Dose Fulvestrant Vs. Loading Dose | Loading Dose Prevents Early Progressions at…
Rita Sanghvi Mehta, MD, UC Irvine Health, explains how Patients were Given Anastrozole + Fulvestrant | Some Patients Over-Represented in…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about SWOG S0226 – for Metastatic Breast Cancer | Addition of Fulvestrant…
Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Schmid, MD, PhD, FRCP,…
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses the promising efficacy data of sacituzumab govitecan, an anti-Trop-2/SN-38…
The treatment landscape of metastatic breast cancer (mBC) is advancing rapidly. Here, Aditya Bardia, MD, MPH, of Massachusetts General Hospital,…
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study…
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of…
Julie Gralow, MD, talks about how to differentiate CDK4/6 inhibitors and whether they can be used interchangeably.
Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in…
Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting,…
Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is…
Neelima Denduluri, MD, talks about how to differentiate CDK4/6 inhibitors and whether they be used interchangeably
Douglas W. Blayney, MD, explains differentiating CDK4/6 Inhibitors and if they can be used interchangeably.
Neelima Denduluri, MD, shares her thoughts on the practice-changing results of the TAILORx study presented at the 2018 Annual Meeting.
Neelima Denduluri, MD, shares her thoughts on the implications of the TAILORx study at the 2018 Annual Meeting.
Sara M. Tolaney, MD, MPH, talks about whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene…
Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means…
Sara M. Tolaney, MD, MPH, the fulvestrant + ribociclib arm of the MONALEESA-3 study
Sara M. Tolaney, MD, MPH, talks about whether CDK4/6 inhibitors can be used interchangeably at Annual Meeting 2018.
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares Use PARP-Inhibitors Early in Therapy for Metastatic Breast…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco explains Talazoparib is Effective in Neoadjuvant Setting | Combine…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trastuzumab-DKST has Regulatory Approval in US |…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1…
Hannah Linden, MD, University of Washington shares Publish New Abstract Data Next Year | Complete Accrual of Estrogen Receptor Imaging…
Hannah Linden, MD, University of Washington shares The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine…
Hannah Linden, MD, University of Washington shares ER Imaging Not Ready for Commercial Use | Working Hard With Tracer Manufacturers…
Hannah Linden, MD, University of Washington shares Estrogen Receptor Imaging | Lobular Tumors Detectable by FES PET
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Therapies for Metastatic Breast Cancer | Clinical Trial Development is Key to…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Triple Negative Breast Cancer Immunotherapies | Pemborlizumab works in NeoAdjuvant Setting at…